10-Q: Azenta, Inc. Reports Q2 2025 Results: Revenue Up, Focus Shifts to Core Businesses

Azenta, Inc. announces a 5% increase in revenue for Q2 2025, driven by growth in Sample Management Solutions and Multiomics, while progressing with the planned sale of its B Medical Systems business.

Summary

• Azenta, Inc. reported a 5% increase in revenue for both the three and six months ended March 31, 2025, reaching $143.4 million and $290.9 million, respectively.
• The revenue growth was primarily driven by the Sample Management Solutions and Multiomics segments.
• Gross margin improved to 46% for both periods, compared to 44% in the prior year, due to higher revenue and margin expansion.
• The company experienced an operating loss of $16.2 million for the quarter and $27.5 million for the six-month period.
• Net loss was $40.5 million for the quarter and $53.8 million for the six-month period, an improvement from the prior year due to decreased losses from discontinued operations.
• The company is proceeding with the planned sale of its B Medical Systems business, classified as held for sale and a discontinued operation.
• The company had cash and cash equivalents, restricted cash, and marketable securities of $513.3 million as of March 31, 2025.
• The company identified material weaknesses in its internal control over financial reporting related to the review of the cash flow statement and the preparation and review of account reconciliations.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While revenue and gross margin improved, the company still reported operating and net losses. The planned sale of a business unit could be seen as a positive strategic move, but the identified material weaknesses in internal control are concerning.

Positives

• Revenue increased by 5% year-over-year, indicating growth in the core business segments.
• Gross margin improved, suggesting better operational efficiency and profitability.
• The planned sale of B Medical Systems will allow management to focus on core businesses.
• The company maintains a strong cash position with $513.3 million in cash, cash equivalents, restricted cash, and marketable securities.

Negatives

• The company reported an operating loss of $16.2 million for the quarter and $27.5 million for the six-month period.
• The company reported a net loss of $40.5 million for the quarter and $53.8 million for the six-month period.
• The company identified material weaknesses in its internal control over financial reporting related to the review of the cash flow statement and the preparation and review of account reconciliations.

Risks

• The company's ability to remediate the identified material weaknesses in internal control over financial reporting is uncertain.
• International trade disputes and tariffs could negatively impact the company's business.
• The BIOSECURE Act could impact the supply of the company's products and services.
• The company's future performance could be affected by various factors, including those described in the 2024 Annual Report on Form 10-K and this Quarterly Report on Form 10-Q under Information Related to Forward-Looking Statements, Part I, Item 1A Risk Factors in the 2024 Annual Report on Form 10-K and Part II, Item 1A Risk Factors in this Quarterly Report on Form 10-Q.

Future Outlook

The company anticipates entering into a definitive agreement to sell its B Medical Systems business by November 2025 and expects to complete the activities included in these initiatives by the end of fiscal year 2025.

Industry Context

The company operates in the life sciences industry, providing sample exploration and management solutions. The results reflect growth in key segments, aligning with the increasing demand for genomic services and sample management.

Comparison to Industry Standards

• It is difficult to compare Azenta's results directly to industry standards without specific competitor data.
• However, companies like Thermo Fisher Scientific, Danaher, and Agilent Technologies are major players in the life sciences tools and services market.
• These companies often report similar metrics such as revenue growth, gross margin, and operating income.
• Azenta's 5% revenue growth is within a reasonable range for companies in this sector, but the operating loss indicates areas for improvement.
• Gross margin of 46% is comparable to some industry peers, but further analysis would be needed to determine Azenta's competitive positioning.

Legal Proceedings

• The Company still may have certain indemnification obligations pursuant to claims made under the definitive agreement it entered into with Edwards in connection with the Company's sale of its semiconductor cryogenics business in the fourth quarter of fiscal year 2018.

Stakeholder Impact

• Shareholders may be concerned about the operating and net losses, as well as the material weaknesses in internal control.
• Employees may experience uncertainty due to the planned sale of the B Medical Systems business and restructuring activities.
• Customers may be affected by changes in the company's product and service offerings as a result of the strategic shift.
• Suppliers and creditors may be impacted by the company's financial performance and strategic decisions.

Next Steps

• The company plans to complete the sale of the B Medical Systems business by November 2025.
• The company intends to remediate the identified material weaknesses in internal control over financial reporting.

Key Dates

Keywords

Azenta, revenue, gross margin, operating loss, net loss, B Medical Systems, Sample Management Solutions, Multiomics, internal control, material weakness, financial results, Q2 2025